SG11201911519UA - AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN - Google Patents
AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEINInfo
- Publication number
- SG11201911519UA SG11201911519UA SG11201911519UA SG11201911519UA SG11201911519UA SG 11201911519U A SG11201911519U A SG 11201911519UA SG 11201911519U A SG11201911519U A SG 11201911519UA SG 11201911519U A SG11201911519U A SG 11201911519UA SG 11201911519U A SG11201911519U A SG 11201911519UA
- Authority
- SG
- Singapore
- Prior art keywords
- amyloid
- protein
- agent
- reducing amount
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017109886 | 2017-06-02 | ||
| JP2017128474 | 2017-06-30 | ||
| PCT/JP2018/021226 WO2018221732A1 (en) | 2017-06-02 | 2018-06-01 | AMYLOID-β PROTEIN LEVEL DECREASING AGENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201911519UA true SG11201911519UA (en) | 2020-01-30 |
Family
ID=64455735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201911519UA SG11201911519UA (en) | 2017-06-02 | 2018-06-01 | AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11666551B2 (en) |
| EP (1) | EP3632429A4 (en) |
| JP (1) | JP7256118B2 (en) |
| KR (1) | KR20200003102A (en) |
| CN (1) | CN110691595A (en) |
| AU (1) | AU2018277983B2 (en) |
| BR (1) | BR112019024983A2 (en) |
| CA (1) | CA3067458C (en) |
| IL (1) | IL270914A (en) |
| MX (1) | MX2019014306A (en) |
| RU (1) | RU2019138538A (en) |
| SG (1) | SG11201911519UA (en) |
| WO (1) | WO2018221732A1 (en) |
| ZA (1) | ZA201907976B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541033B2 (en) | 2017-06-02 | 2023-01-03 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating Alzheimer's disease |
| NZ759647A (en) | 2017-06-02 | 2022-02-25 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating spinocerebellar ataxia |
| BR112019024851A2 (en) | 2017-06-02 | 2020-06-09 | Fujifilm Toyama Chemical Co Ltd | agent to prevent or treat cerebral atrophy |
| US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1019091A4 (en) | 1997-09-05 | 2005-05-11 | Human Genome Sciences Inc | 50 human secreted proteins |
| GB9824207D0 (en) | 1998-11-04 | 1998-12-30 | Zeneca Ltd | Neurological disorders |
| BRPI0213393B8 (en) | 2001-10-19 | 2021-05-25 | Fujifilm Toyama Chemical Co Ltd | alkyl ether derivatives, or one of its salts, process for producing an alkyl ether derivative, alkyl amide derivative, or one of its salts, and pharmaceutical composition |
| PL217394B1 (en) | 2002-06-14 | 2014-07-31 | Toyama Chemical Co Ltd | Medicinal compositions improving brain function and method for improving brain function |
| NZ543100A (en) | 2003-04-17 | 2008-07-31 | Toyama Chemical Co Ltd | Preventive/remedy for retinal nerve dieases containing alkyl ether derivatives or salts thereof |
| US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| KR101374593B1 (en) | 2006-04-26 | 2014-03-17 | 토야마 케미칼 컴퍼니 리미티드 | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| ES2550367T3 (en) | 2008-03-04 | 2015-11-06 | Vernalis (R&D) Ltd. | Azetidine derivatives |
| FR2934596B1 (en) | 2008-07-30 | 2015-04-10 | Trophos | NOVEL CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND PROCESS FOR PREPARING THE SAME |
| US20110262442A1 (en) | 2009-11-06 | 2011-10-27 | Adenios, Inc. | Compositions for treating cns disorders |
| US9872914B2 (en) | 2012-02-22 | 2018-01-23 | Toyama Chemical Co., Ltd. | Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof |
| EP2874997A4 (en) | 2012-07-19 | 2016-01-06 | Univ Drexel | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
| CA2882525A1 (en) | 2012-10-01 | 2014-04-10 | F. Hoffman-La Roche Ag | Benzimidazoles as cns active agents |
| KR102346219B1 (en) | 2014-01-31 | 2022-01-04 | 후지필름 도야마 케미컬 가부시키가이샤 | Post nerve injury rehabilitation effect-enhancing agent comprising alkylether derivative or salt thereof |
| WO2015163318A1 (en) | 2014-04-25 | 2015-10-29 | レジリオ株式会社 | Therapeutic agent for diseases associated with nerve axon dysfunction, including therapeutic agent for alzheimer's disease |
| WO2015188368A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| WO2016051799A1 (en) | 2014-10-01 | 2016-04-07 | 学校法人同志社 | 2-aminohydroquinone derivative and tau aggregation inhibitor |
| KR102621513B1 (en) | 2015-02-02 | 2024-01-04 | 유씨비 바이오파마 에스알엘 | 9H-pyrrolo-dipyridine derivatives |
| US20160324851A1 (en) | 2015-05-07 | 2016-11-10 | Axovant Sciences, Ltd. | Methods of treating a neurodegenerative disease |
| EP3308782B1 (en) | 2015-06-11 | 2022-01-19 | Toyama Chemical Co., Ltd. | Sigma-receptor binding agent |
| BR112018011948B1 (en) | 2015-12-25 | 2023-10-03 | Fujifilm Toyama Chemical Co., Ltd | TABLET COMPRISING 1-(3-(2-(1-BENZOTIOPHEN-5-YL)ETOXY)PROPYL) AZETIDIN-3-OL OR SALT THEREOF |
| BR112019024851A2 (en) | 2017-06-02 | 2020-06-09 | Fujifilm Toyama Chemical Co Ltd | agent to prevent or treat cerebral atrophy |
| NZ759647A (en) | 2017-06-02 | 2022-02-25 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating spinocerebellar ataxia |
| KR20220101001A (en) | 2017-06-02 | 2022-07-18 | 후지필름 도야마 케미컬 가부시키가이샤 | Agent for preventing or treating tauopathy |
| US11541033B2 (en) | 2017-06-02 | 2023-01-03 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating Alzheimer's disease |
| US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
-
2018
- 2018-06-01 CA CA3067458A patent/CA3067458C/en active Active
- 2018-06-01 KR KR1020197035350A patent/KR20200003102A/en not_active IP Right Cessation
- 2018-06-01 SG SG11201911519UA patent/SG11201911519UA/en unknown
- 2018-06-01 CN CN201880035521.7A patent/CN110691595A/en active Pending
- 2018-06-01 WO PCT/JP2018/021226 patent/WO2018221732A1/en active Application Filing
- 2018-06-01 MX MX2019014306A patent/MX2019014306A/en unknown
- 2018-06-01 US US16/617,607 patent/US11666551B2/en active Active
- 2018-06-01 BR BR112019024983-4A patent/BR112019024983A2/en active Search and Examination
- 2018-06-01 RU RU2019138538A patent/RU2019138538A/en unknown
- 2018-06-01 JP JP2019521351A patent/JP7256118B2/en active Active
- 2018-06-01 EP EP18809110.2A patent/EP3632429A4/en not_active Withdrawn
- 2018-06-01 AU AU2018277983A patent/AU2018277983B2/en active Active
-
2019
- 2019-11-25 IL IL270914A patent/IL270914A/en unknown
- 2019-11-29 ZA ZA2019/07976A patent/ZA201907976B/en unknown
-
2023
- 2023-03-03 US US18/116,914 patent/US20230310371A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210137880A1 (en) | 2021-05-13 |
| EP3632429A4 (en) | 2020-06-10 |
| EP3632429A1 (en) | 2020-04-08 |
| JPWO2018221732A1 (en) | 2020-04-02 |
| IL270914A (en) | 2020-01-30 |
| KR20200003102A (en) | 2020-01-08 |
| JP7256118B2 (en) | 2023-04-11 |
| RU2019138538A (en) | 2021-07-09 |
| US11666551B2 (en) | 2023-06-06 |
| WO2018221732A1 (en) | 2018-12-06 |
| AU2018277983A1 (en) | 2019-12-19 |
| CN110691595A (en) | 2020-01-14 |
| BR112019024983A2 (en) | 2020-06-23 |
| CA3067458C (en) | 2022-11-01 |
| RU2019138538A3 (en) | 2021-07-09 |
| CA3067458A1 (en) | 2018-12-06 |
| US20230310371A1 (en) | 2023-10-05 |
| MX2019014306A (en) | 2022-06-09 |
| AU2018277983B2 (en) | 2021-04-08 |
| ZA201907976B (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249058A1 (en) | Compounds and methods for the enhanced degradation of targeted proteins | |
| HK1252757A1 (en) | Compositions and methods for degradation of misfolded proteins | |
| IL259123B (en) | Two-part compositions for application over skin | |
| HK1255383A1 (en) | Peptides and antibodies for the removal of biofilms | |
| IL289789A (en) | Compounds and methods for reducing tau expression | |
| GB201514756D0 (en) | Compound and method of use | |
| ZA201907976B (en) | AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN | |
| HK1245030A1 (en) | Chemically minimized system for time reduced application of eyelash extensions | |
| GB201514760D0 (en) | Compounds and method of use | |
| EP3218370A4 (en) | Methods and compositions for inhibition of bromodomain and extraterminal proteins | |
| PT3297628T (en) | Calcineurin inhibitors of the setron family for the treatment of hearing loss | |
| SG10201912134TA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| IL283332A (en) | Compounds and methods for reducing prion expression | |
| HK1257689A1 (en) | COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α | |
| GB201721463D0 (en) | Tailored dose of contrast agent | |
| IL259710A (en) | Compositions and methods of treatment for mvid and related diseases | |
| ZA201800175B (en) | Methods and compositions for selective regulation of protein expression | |
| EP3894768C0 (en) | Methods of cryo-curing | |
| PT3320901T (en) | Application of dimethylamino micheliolide | |
| IL260369A (en) | Inhibition of protein degradation for improved production | |
| SG11202105136WA (en) | Application of chidamide | |
| GB201506567D0 (en) | Acccumilation of floating-point valves | |
| HK1250343A1 (en) | Calcineurin inhibitors of the setron family for the treatment of hearing loss | |
| AU2017901032A0 (en) | Trafficking of amyloid precursor protein | |
| EP3440210A4 (en) | Compositions and methods for selective inhibition of grainyhead-like protein expression |